Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...
Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare ...
Researchers linked higher weight loss after initiating antiobesity meds to lower risk for revision of hip and knee replacement.
Stanford Medicine researchers have identified a naturally occurring molecule that mimics the appetite-suppressing effects of ...
It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity ...
A naturally occurring molecule that works as effectively as other semaglutide-based drugs — without the common side effects — ...
It seems like no matter what I do, I can't lose weight. Most of my family members struggle with their weight too. Do our ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback